Author

Beatrijs Strubbe

ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL
ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

Beatrijs Strubbe  et al.

Item 1 - 1 / 1
1